vs

Side-by-side financial comparison of Arhaus, Inc. (ARHS) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Arhaus, Inc. is the larger business by last-quarter revenue ($364.8M vs $207.3M, roughly 1.8× Ultragenyx Pharmaceutical Inc.). Arhaus, Inc. runs the higher net margin — 4.1% vs -62.0%, a 66.2% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 5.1%). Arhaus, Inc. produced more free cash flow last quarter ($-8.8M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 11.2%).

Arhaus, Inc. is an upscale American home furnishings company headquartered in Boston Heights, Ohio. Founded in 1986 with a focus on sustainability and artisanship in product quality, Arhaus provides a diversified assortment of specialty goods and services addressing omnichannel direct-to-consumer and business-to-business residential and commercial operations.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

ARHS vs RARE — Head-to-Head

Bigger by revenue
ARHS
ARHS
1.8× larger
ARHS
$364.8M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+20.8% gap
RARE
25.9%
5.1%
ARHS
Higher net margin
ARHS
ARHS
66.2% more per $
ARHS
4.1%
-62.0%
RARE
More free cash flow
ARHS
ARHS
$92.0M more FCF
ARHS
$-8.8M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
11.2%
ARHS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ARHS
ARHS
RARE
RARE
Revenue
$364.8M
$207.3M
Net Profit
$15.1M
$-128.6M
Gross Margin
38.1%
Operating Margin
5.6%
-54.7%
Net Margin
4.1%
-62.0%
Revenue YoY
5.1%
25.9%
Net Profit YoY
-29.1%
3.5%
EPS (diluted)
$0.11
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARHS
ARHS
RARE
RARE
Q4 25
$364.8M
$207.3M
Q3 25
$344.6M
$159.9M
Q2 25
$358.4M
$166.5M
Q1 25
$311.4M
$139.3M
Q4 24
$347.0M
$164.6M
Q3 24
$319.1M
$139.5M
Q2 24
$309.8M
$147.0M
Q1 24
$295.2M
$108.8M
Net Profit
ARHS
ARHS
RARE
RARE
Q4 25
$15.1M
$-128.6M
Q3 25
$12.2M
$-180.4M
Q2 25
$35.1M
$-115.0M
Q1 25
$4.9M
$-151.1M
Q4 24
$21.3M
$-133.2M
Q3 24
$9.9M
$-133.5M
Q2 24
$22.2M
$-131.6M
Q1 24
$15.1M
$-170.7M
Gross Margin
ARHS
ARHS
RARE
RARE
Q4 25
38.1%
Q3 25
38.7%
Q2 25
41.4%
Q1 25
37.1%
Q4 24
40.0%
Q3 24
38.6%
Q2 24
40.1%
Q1 24
39.0%
Operating Margin
ARHS
ARHS
RARE
RARE
Q4 25
5.6%
-54.7%
Q3 25
4.8%
-106.9%
Q2 25
13.0%
-64.8%
Q1 25
1.7%
-102.6%
Q4 24
8.2%
-74.3%
Q3 24
3.3%
-94.6%
Q2 24
9.5%
-79.1%
Q1 24
6.2%
-151.9%
Net Margin
ARHS
ARHS
RARE
RARE
Q4 25
4.1%
-62.0%
Q3 25
3.5%
-112.8%
Q2 25
9.8%
-69.0%
Q1 25
1.6%
-108.5%
Q4 24
6.1%
-80.9%
Q3 24
3.1%
-95.7%
Q2 24
7.2%
-89.5%
Q1 24
5.1%
-156.8%
EPS (diluted)
ARHS
ARHS
RARE
RARE
Q4 25
$0.11
$-1.28
Q3 25
$0.09
$-1.81
Q2 25
$0.25
$-1.17
Q1 25
$0.03
$-1.57
Q4 24
$0.15
$-1.34
Q3 24
$0.07
$-1.40
Q2 24
$0.16
$-1.52
Q1 24
$0.11
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARHS
ARHS
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$253.4M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$418.2M
$-80.0M
Total Assets
$1.4B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARHS
ARHS
RARE
RARE
Q4 25
$253.4M
$421.0M
Q3 25
$262.2M
$202.5M
Q2 25
$234.8M
$176.3M
Q1 25
$214.4M
$127.1M
Q4 24
$197.5M
$174.0M
Q3 24
$177.7M
$150.6M
Q2 24
$174.2M
$480.7M
Q1 24
$233.2M
$112.3M
Stockholders' Equity
ARHS
ARHS
RARE
RARE
Q4 25
$418.2M
$-80.0M
Q3 25
$400.4M
$9.2M
Q2 25
$385.6M
$151.3M
Q1 25
$348.8M
$144.2M
Q4 24
$343.7M
$255.0M
Q3 24
$320.6M
$346.8M
Q2 24
$309.3M
$432.4M
Q1 24
$285.6M
$140.3M
Total Assets
ARHS
ARHS
RARE
RARE
Q4 25
$1.4B
$1.5B
Q3 25
$1.4B
$1.2B
Q2 25
$1.3B
$1.3B
Q1 25
$1.3B
$1.3B
Q4 24
$1.2B
$1.5B
Q3 24
$1.2B
$1.5B
Q2 24
$1.2B
$1.6B
Q1 24
$1.2B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARHS
ARHS
RARE
RARE
Operating Cash FlowLast quarter
$9.3M
$-99.8M
Free Cash FlowOCF − Capex
$-8.8M
$-100.8M
FCF MarginFCF / Revenue
-2.4%
-48.6%
Capex IntensityCapex / Revenue
5.0%
0.5%
Cash ConversionOCF / Net Profit
0.62×
TTM Free Cash FlowTrailing 4 quarters
$59.0M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARHS
ARHS
RARE
RARE
Q4 25
$9.3M
$-99.8M
Q3 25
$46.1M
$-91.4M
Q2 25
$34.9M
$-108.3M
Q1 25
$46.5M
$-166.5M
Q4 24
$31.7M
$-79.3M
Q3 24
$31.1M
$-67.0M
Q2 24
$47.5M
$-77.0M
Q1 24
$36.8M
$-190.7M
Free Cash Flow
ARHS
ARHS
RARE
RARE
Q4 25
$-8.8M
$-100.8M
Q3 25
$28.0M
$-92.7M
Q2 25
$20.9M
$-110.7M
Q1 25
$18.9M
$-167.8M
Q4 24
$13.0M
$-79.5M
Q3 24
$4.6M
$-68.6M
Q2 24
$11.3M
$-79.0M
Q1 24
$10.9M
$-193.9M
FCF Margin
ARHS
ARHS
RARE
RARE
Q4 25
-2.4%
-48.6%
Q3 25
8.1%
-58.0%
Q2 25
5.8%
-66.5%
Q1 25
6.1%
-120.5%
Q4 24
3.7%
-48.3%
Q3 24
1.4%
-49.2%
Q2 24
3.6%
-53.7%
Q1 24
3.7%
-178.2%
Capex Intensity
ARHS
ARHS
RARE
RARE
Q4 25
5.0%
0.5%
Q3 25
5.3%
0.8%
Q2 25
3.9%
1.5%
Q1 25
8.9%
1.0%
Q4 24
5.4%
0.1%
Q3 24
8.3%
1.2%
Q2 24
11.7%
1.4%
Q1 24
8.8%
3.0%
Cash Conversion
ARHS
ARHS
RARE
RARE
Q4 25
0.62×
Q3 25
3.77×
Q2 25
1.00×
Q1 25
9.53×
Q4 24
1.49×
Q3 24
3.14×
Q2 24
2.14×
Q1 24
2.44×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARHS
ARHS

Sales Channel Retail$305.7M84%
Sales Channel E Commerce$59.2M16%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons